PMS-CLINDAMYCIN CAPSULE

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE)

Disponible desde:

PHARMASCIENCE INC

Código ATC:

J01FF01

Designación común internacional (DCI):

CLINDAMYCIN

Dosis:

300MG

formulario farmacéutico:

CAPSULE

Composición:

CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 300MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

LINCOMYCINS

Resumen del producto:

Active ingredient group (AIG) number: 0105830003; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2016-10-26

Ficha técnica

PRODUCT MONOGRAPH
PR
PMS-CLINDAMYCIN
clindamycin hydrochloride capsules, USP
clindamycin 150 mg, 300 mg
ANTIBIOTIC
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite 100
July 13, 2016
Montréal, Québec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO.: 195698
_pms-CLINDAMYCIN Product Monograph_ Page 2 of 28_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
10
OVERDOSAGE
........................................................................................................................
11
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
12
STORAGE
AND
STABILITY..................................................................................................
13
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
15
PHARMACEUTICAL
INFORMATION
.................................................................................
15
DETAILED
PHARMACOLOGY...............................................